Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14574000 | 1.00 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2CYP1A2 | |
| SCHEMBL4264816 | 0.94 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2RIPK1 | |
| SCHEMBL5150650 | 0.91 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2CYP1A2 | |
| SCHEMBL21810823 | 0.91 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2CYP1A2 | |
| SCHEMBL3860447 | 0.90 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2LMNA | |
| SCHEMBL13778500 | 0.89 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2RIPK1 | |
| SCHEMBL25484839 | 0.89 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2RIPK1 | |
| SCHEMBL3860744 | 0.89 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2RIPK1 | |
| SCHEMBL12799226 | 0.89 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2KDM4E | |
| SCHEMBL32687402 | 0.88 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217071-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4076667-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022066805-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021127404-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2018216822-A1 | NOVEL IMIDAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-29 | — | — | WO | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | CYP3A4 3351/4885HTT 4210/4885SMN1; SMN2 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.